ADH1B and neoplasm: Decrease/loss of ADH1B in MFs during the adenoma-carcinoma sequence contributes to disruption of the retinol-mediated suppression of tumor-promoting inflammation in CRC and to the increase of IL-6 in neoplastic tissue.